Loading...
SWTX logo

SpringWorks Therapeutics, Inc.Informe acción NasdaqGS:SWTX

Capitalización bursátil US$3.5b
Precio de las acciones
n/a
1Y26.0%
7D0.04%
1D0.02%
Valor de la cartera
​
Ver

SpringWorks Therapeutics, Inc.

Informe acción NasdaqGS:SWTX

Capitalización de mercado: US$3.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

SpringWorks Therapeutics (SWTX) Resumen de Acciones

SpringWorks Therapeutics, Inc. es una empresa biofarmacéutica en fase comercial dedicada al desarrollo y la comercialización de medicamentos para poblaciones de pacientes desatendidas que padecen enfermedades raras y cáncer. Saber más

Análisis fundamental de SWTX
Puntuación del snowflake
Valoración0/6
Crecimiento futuro5/6
Rendimiento pasado0/6
Salud financiera6/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 62.07%

Análisis de riesgos

No se han detectado riesgos en SWTX a partir de nuestros controles de riesgos.

SWTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW485,737 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
485,737 investors already sharing narratives
View all narratives

Competidores de SpringWorks Therapeutics, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del SpringWorks Therapeutics
Precios históricos de las acciones
Precio actual de la acciónUS$46.99
Máximo en las últimas 52 semanasUS$62.00
Mínimo de 52 semanasUS$28.21
Beta0.70
Cambio en 1 mes0.69%
Variación en 3 meses9.10%
Cambio de 1 año26.05%
Variación en 3 años68.66%
Variación en 5 años13.23%
Variación desde la OPV107.64%

Noticias y actualizaciones recientes

Recent updates

Seeking Alpha • Apr 29

SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO

Summary Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline. Expansion opportunities for OGSIVEO include potential European approval for desmoid tumors and trials for relapsed/refractory ovarian granulosa cell tumors. GOMEKLI's approval for NF1-PN patients and ongoing European review further enhance SpringWorks' pipeline value. GOMEKLI is also being explored in a phase 1/2 open-label study to treat pediatric and adult patients with low-grade gliomas. Read the full article on Seeking Alpha
Artículo de análisis • Mar 12

SpringWorks Therapeutics, Inc.'s (NASDAQ:SWTX) Shares Climb 26% But Its Business Is Yet to Catch Up

The SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) share price has done very well over the last month, posting an...
Seeking Alpha • Mar 11

SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

Summary SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children. SpringWorks is also working on new potential indications for its IP portfolio while running additional trials and even attracting M&A interest from larger players. In my view, SWTX stock’s valuation has a bit of premium embedded in it, but it looks well deserved. In fact, I believe it’s a good speculative “Buy” at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

Summary SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025. The company has $498 million in cash as of September 30th of 2024, which is sufficient to fund its operations into the first half of 2026. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

Summary SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting. Despite current valuation concerns, SWTX's fundamentals and potential sales growth justify a "Buy" sentiment for the stock. Read the full article on Seeking Alpha
Seeking Alpha • Dec 15

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Summary Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. SpringWorks Therapeutics has promising data with multiple launches planned for next year. Tarsus Pharmaceuticals' lead drug shows strong launch metrics, suggesting significant upside potential despite its current market cap. Read the full article on Seeking Alpha
Artículo de análisis • Nov 15

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

It's been a pretty great week for SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders, with its shares surging...
Seeking Alpha • Nov 04

SpringWorks Therapeutics Merits A Speculative Buy

Summary Since we last visited SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding to get the company to profitability in the years ahead. An updated analysis around SpringWorks Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Summary SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and potential approval for mirdametinib in 2025 position SWTX well for growth. SWTX's strong commercial execution and expanding product portfolio indicate the potential for profitability and market appreciation. Read the full article on Seeking Alpha
Artículo de análisis • May 11

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

SpringWorks Therapeutics, Inc. ( NASDAQ:SWTX ) shareholders will have a reason to smile today, with the analysts making...
Artículo de análisis • May 03

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Apr 25

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Summary SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully commercializing its therapy. With rapidly growing losses and its hefty market cap SpringWorks Therapeutics is a "Hold". Read the full article on Seeking Alpha
Seeking Alpha • Apr 19

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Summary SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo for the treatment of desmoid tumors in November last year. Ogsiveo is the first therapy approved for desmoid tumors, with a market opportunity estimated at $2.2 billion. Sales in Q4 2023 were just $5m, however, while net loss was $325m. Ogsiveo could win approval in Europe and also in a new indication Ovarian Granulosa Cell Tumors, opening up larger markets. A second candidate, mirdametinib, may be on track for approval in the rare disease NF-1, and is being evaluated in oncology settings also - as is nirogacestat (Ogsiveo). With more early stage programs, and multiple catalysts in play, some may feel SpringWorks's shares - up over 70% on a 12-months basis - can realise further upside. There is alot of uncertainty, however, which I why I maintain a "hold" rating. Read the full article on Seeking Alpha
Artículo de análisis • Sep 20

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Jun 07

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Feb 22

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Nov 09

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Rentabilidad de los accionistas

SWTXUS BiotechsMercado US
7D0.04%-3.6%-0.9%
1Y26.0%33.3%19.1%

Rentabilidad vs. Industria: SWTX superó a la industria US Biotechs, que obtuvo un rendimiento del 33.3% el año pasado.

Rentabilidad vs. Mercado: SWTX superó al mercado US, que obtuvo un rendimiento del 19.1% el año pasado.

Volatilidad de los precios

Is SWTX's price volatile compared to industry and market?
SWTX volatility
SWTX Average Weekly Movement6.4%
Biotechs Industry Average Movement10.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Precio estable de las acciones: SWTX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de SWTX (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2017368Saqib Islamwww.springworkstx.com

SpringWorks Therapeutics, Inc, empresa biofarmacéutica en fase comercial, se dedica al desarrollo y la comercialización de medicamentos para poblaciones de pacientes desatendidas que padecen enfermedades raras y cáncer. Ofrece OGSIVEO (nirogacestat), un inhibidor oral de la gamma secretasa de molécula pequeña para el tratamiento de tumores desmoides; y GOMEKLI (mirdametinib), un inhibidor oral de MEK1 y MEK2 de molécula pequeña para el tratamiento de pacientes adultos y pediátricos a partir de dos años de edad con neurofibromatosis tipo 1 asociada a neurofibromas plexiformes (NF1-PN). La empresa también desarrolla Nirogacestat, también en fase 2 de desarrollo clínico como monoterapia para el tratamiento de tumores de células de la granulosa ovárica (TCG), un subtipo de cáncer de ovario; y mirdametinib para el tratamiento de tumores sólidos que albergan otras aberraciones MAPK, incluido para el tratamiento de pacientes pediátricos y adultos jóvenes con gliomas de bajo grado que se encuentra en fase 1/2 de ensayo clínico.

Resumen de fundamentos de SpringWorks Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de SpringWorks Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de SWTX
Capitalización bursátilUS$3.54b
Beneficios(TTM)-US$253.93m
Ingresos (TTM)US$219.67m
16.1x
Ratio precio-ventas (PS)
-13.9x
Ratio precio-beneficio (PE)

¿Está SWTX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SWTX
IngresosUS$219.67m
Coste de los ingresosUS$14.88m
Beneficio brutoUS$204.80m
Otros gastosUS$458.73m
Beneficios-US$253.93m

Últimos beneficios comunicados

Mar 31, 2025

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-3.37
Margen bruto93.23%
Margen de beneficio neto-115.60%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado SWTX a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2025/07/02 11:42
Precio de las acciones al final del día2025/06/30 00:00
Beneficios2025/03/31
Ingresos anuales2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

SpringWorks Therapeutics, Inc. está cubierta por 4 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Cory KasimovEvercore ISI
Corinne JohnsonGoldman Sachs
Michael SchmidtGuggenheim Securities, LLC